Product Details
| Product Name:
PR-Set7 Protein, Human, Recombinant |
Supply Ability:
10g |
| Release date:
2026/04/20 |
Product Introduction
Bioactivity
| Name | PR-Set7 Protein, Human, Recombinant |
| Description | KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. Inhibition of KMT5A attenuated proliferation and induced apoptosis. Elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid cancer. KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma. |
| Storage | Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6 months
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | SET-8 | SET-07 | SET 8 | SET 07 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$45.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-07-17 |
|
|
$3150.00
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-15 |
|
|
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 |
United States